Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics was founded in 1990 as Shearwater Polymers and later rebranded as Inhale Therapeutic Systems, originally focused on pulmonary drug-delivery technology. Howard Robin joined as CEO in 2007, shifting the firm's strategic core toward immunology and oncology through a proprietary polymer-conjugation platform. The company operates from San Francisco with a significant manufacturing and development site in Huntsville, Alabama, and has historically been listed on NASDAQ under the ticker NKTR. Nektar deploys capital almost entirely into internal research and clinical trials rather than a diversified investment portfolio. Its core asset has been bempegaldesleukin (bempeg), a CD122-biased interleukin-2 pathway agonist engineered to stimulate cancer-killing immune cells without the toxicity of native IL-2. The program advanced through multiple registration trials, including a pivotal Phase 3 study with Bristol Myers Squibb in melanoma, which failed to meet its endpoints in 2022. The firm subsequently restructured, eliminating roughly 70 percent of its San Francisco workforce and pivoting resources toward earlier-stage immunology assets. Other disclosed drug candidates include NKTR-255 and NKTR-358, the latter partnered with Eli Lilly in a global licensing deal. As of mid-2023, the company held approximately $350 million in cash and marketable securities following a major cost-cutting initiative. Nektar has historically sustained itself through a combination of equity financings, partnership milestones, and royalty streams — most notably from the anti-infectives portfolio Pfizer acquired from Nektar in 2006. The Huntsville facility provides a distinct capability set, handling complex sterile-injectable manufacturing. In September 2023: Initiated a Phase 2b study of rezpegaldesleukin (NKTR-358) in atopic dermatitis, repositioning the pipeline around autoimmune disorders after the oncology setbacks (per the firm, September 2023). Nektar's structural differentiator lies in a deep manufacturing and polymer-engineering infrastructure that is unusual for a biotechnology company of its size. While most peers contract out production, Nektar owns the polymer-chemistry supply chain that underpins its conjugates, giving it a vertically integrated, patent-protected operation in Alabama. The succession challenge is acute: Howard Robin has been the singular strategic force since 2007, and the recent clinical failures triggered a retrenchment that leaves the firm's future largely contingent on the Lilly-partnered autoimmune pipeline maturing into a commercial revenue driver.